AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03387098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03387098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study NCT03387098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
Study NCT03387098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for infusion
Description: NK-92 \[CD16.158V, ER IL-2\]
Study NCT02065362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNR.NPC-specific T cells
Description: Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:~Dose Level 1:~Day 0: 2 x 10\^7 cells/m\^2~Day 14: 2 x 10\^7 cells/m\^2~The doses are calculated according to the total T cell number.
Study NCT02065362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNR.NPC-specific T cells + cyclophosphamide + fludarabine
Description: Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.~Each patient will receive infusions according to the following dosing schedule:~Dose Level 2:~Cy/Flu on Days -4 to -2 and then 4 x 10\^7 cells/m\^2 on Day 0, Day 1 or Day 2~Dose Level 3:~Cy/Flu on Days -4 to -2 and then 1 x 10\^8 cells/m\^2 on Day 0, Day 1, or Day 2
Study NCT02797457 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prosthetic forehands
Description: Prosthetic forehands
Study NCT03387098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody
Study NCT01872156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention GESTABAC
Description: Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth.
Study NCT01872156 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The group control will act according to usual management.
Study NCT02312609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline hydrochloride
Description: extended release tablets 135 mg
Study NCT02312609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride
Description: extended release tablets 135 mg
Study NCT02609035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic prompt
Study NCT02733835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
Study NCT01407302 — intervention group
Intervention type: OTHER
Intervention: Head rotation
Description: Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
Study NCT03473366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tao Mask
Description: All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
Study NCT03387098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal
Study NCT03387098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT04119050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 injection administered as intravenous infusion
Study NCT03387098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03387098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03387098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study NCT03387098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study NCT03387098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovaza
Description: Omega-3-acid ethyl esters
Study NCT03387098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study NCT03387098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study NCT04119050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered as intravenous infusion
Study NCT03523442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: The participants will receive apalutamide 240 mg once daily orally.
Study NCT02220465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA+ Smoking Cessation (LMPA)
Study NCT02220465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Smoking Counseling (SCC)
Study NCT00171496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion
Study NCT03473366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mask
Description: Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
Study NCT01443338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptergium Wilfordii
Description: Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
Study NCT01443338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
Study NCT00171496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT00294723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg for s.c. (under the skin) injection
Study NCT00294723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: 8 mg capsule
Study NCT00294723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg for s.c. (under the skin) injection
Study NCT00294723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo, 8mg capsule
Study NCT00294723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo, 200 mcl
Study NCT00294723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo, 300 mcl
Study NCT01482156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 + BEZ235
Description: RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
Study NCT02375126 — intervention group
Intervention type: PROCEDURE
Intervention: Electroencephalography
Description: Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
Study NCT04161144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
Study NCT01570972 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Cognitive Behavioral Therapy
Description: weekly
Study NCT01570972 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multifamily Group Psychoeducation
Description: twice monthly
Study NCT05713396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril
Description: Per os
Study NCT05713396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Per os
Study NCT05713396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril + Losartan
Description: Per os
Study NCT01883817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA Omega-3
Description: Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
Study NCT01883817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
Study NCT03065959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reldesemtiv
Description: oral
Study NCT03065959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study NCT04494061 — intervention group
Intervention type: PROCEDURE
Intervention: blood collection
Description: Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.
Study NCT04664959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB16 (Proposed Denosumab Biosimilar)
Description: Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously.
Study NCT04664959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB16 (Proposed Denosumab Biosimilar)
Description: Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously.
Study NCT01945853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7 Tesla MRI
Study NCT00833482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
Study NCT00833482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
Study NCT00833482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.~Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.
Study NCT01003483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orlistat
Description: Tablet,120mg,three times a day,three months
Study NCT04664959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia® (Denosumab)
Description: Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
Study NCT01594190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity 15 minutes/day
Description: weight-bearing treadmill, pulsereserve increase of 50 %
Study NCT01594190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity, 2 x 30 minutes/day
Description: weight-bearing treadmill, pulsereserve increase of 50 %
Study NCT00003762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT04101487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash Transfer
Description: Monthly cash transfers
Study NCT04101487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash Transfers and Nutrition Education
Description: Cash transfers every month and structured nutrition education provided at household level by community health assistants based on a nutrition education handbook
Study NCT00003762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT02433821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Study NCT02982174 — intervention group
Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: Image acquisition of the posterior surface of the eye
Study NCT02982174 — intervention group
Intervention type: DEVICE
Intervention: DRI OCT Triton
Description: Image acquisition of the posterior surface of the eye
Study NCT03719248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG
Study NCT02336360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.
Study NCT02126423 — intervention group
Intervention type: OTHER
Intervention: Conjunctival and nasopharyngeal swabs
Description: For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.
Study NCT00746707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1. Dermabond Topical Skin Adhesive 2-Octyl Cyanoacrylate
Description: adhesive of perineal tears
Study NCT00746707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3. traditional suturing with vicryl rapid 2X0
Description: suturing of perineal tears grade one with vicryl rapid 2X0
Study NCT01542437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug.
Study NCT03545594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered in home rehabilitation
Description: Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts before the Corona pandemic and eight sessions with up to six of them video delivered if necessary during the Corona pandemic ) delivered over a 4-month period in three phases
Study NCT03545594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual follow-up in the municipality
Study NCT02048098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Description: 400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
Study NCT02048098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buccal misoprostol
Description: 400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
Study NCT04123418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WVT078
Description: WVT078 will be administered IV (intravenously) in a dose escalation schedule
Study NCT04123418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WHG626
Description: WHG626 will be administered orally in a dose escalation schedule
Study NCT04530110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.~Participants weighing \< threshold will receive Dose B subcutaneously monthly.~Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.
Study NCT03512327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autoimmune protocol (AIP) diet
Description: Autoimmune protocol diet, designed as a 6 week step wise elimination phase followed by 5 week maintenance phase.
Study NCT04161144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
Study NCT02622204 — intervention group
Intervention type: PROCEDURE
Intervention: Corrective osteotomy
Description: corrective osteotomy for varus alignment
Study NCT01099384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written self-help materials
Description: Written materials to help adolescents stop tobacco use
Study NCT01099384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group behavioral counseling
Description: group behavioral counseling (2 day weekend program)
Study NCT03534986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: International Biophysics AffloVest
Description: High-frequency chest wall oscillation vest
Study NCT03534986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hill-Rom The Vest
Description: High-frequency chest wall oscillation vest
Study NCT03534986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respirtech inCourage
Description: High-frequency chest wall oscillation vest
Study NCT03534986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromed SmartVest
Description: High-frequency chest wall oscillation vest
Study NCT02898649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25\~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.